This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
wdt	http://www.wikidata.org/prop/direct/
wdtn	http://www.wikidata.org/prop/direct-normalized/
n11	http://dx.doi.org/10.1016/
schema	http://schema.org/
rdfs	http://www.w3.org/2000/01/rdf-schema#
skos	http://www.w3.org/2004/02/skos/core#
wikibase	http://wikiba.se/ontology#
p	http://www.wikidata.org/prop/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n9	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdh	http://www.w3.org/2001/XMLSchema#
wds	http://www.wikidata.org/entity/statement/
wd	http://www.wikidata.org/entity/

Statements

Subject Item

wd:Q75344763

rdf:type

wikibase:Item

schema:description

artikull shkencor i botuar më 01 shkurt 2004 наукова стаття, опублікована в лютому 2004 im Februar 2004 veröffentlichter wissenschaftlicher Artikel wetenschappelijk artikel artículu científicu espublizáu en febreru de 2004 scientific article published on 01 February 2004

p:P577

wds:Q75344763-93C804F5-80C0-4B95-BD34-EB32259A4756

wdt:P577

2004-02-01T00:00:00Z

p:P2093

wds:Q75344763-1F241676-C343-46E2-B4DF-F2CB2C2CB727 wds:Q75344763-08F907FB-AE2D-4EF5-B1E5-31F8CE015C41 wds:Q75344763-14300B32-E663-4EED-A058-F56BFDF51FA8 wds:Q75344763-8E337F35-AF5A-4B4A-89AE-9BF8BB8F9F9A wds:Q75344763-5103D73F-365F-4D50-81F6-DBF737C0D2C5 wds:Q75344763-8945AEF8-B37B-4AC8-ABA3-59AA4480C07D wds:Q75344763-EA76B311-0C64-4257-8AA2-2B0EA52EA59E wds:Q75344763-DDE64062-526B-4DF9-A95D-47F699C607BF wds:Q75344763-E882F408-02C5-4915-813E-F9C22B567B89 wds:Q75344763-D2EE680D-CDB2-4EFB-9697-13BAF79AFF15

wdt:P2093

U R Kleeberg D Liénard A M M Eggermont D J Ruiter C Chartier E B Bröcker J Marsden S Suciu EORTC Melanoma Group in cooperation with the German Cancer Society (DKG) D Schadendorf

rdfs:label

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary

skos:prefLabel

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary

schema:name

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast

p:P1476

wds:Q75344763-D983E535-FD0A-4484-AE24-1AED6EDA1E11

wdt:P1476

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis

p:P304

wds:Q75344763-3E23197E-E371-4549-8BC2-C750469D81F6

wdt:P304

390-402

p:P31

wds:Q75344763-3070CEE6-91AB-40A6-997C-39822B21B4BE

wdt:P31

wd:Q13442814

p:P921

wds:Q75344763-F2849185-AD79-4CEF-865F-E79E12E9F286

wdt:P921

wd:Q42824827

p:P698

wds:Q75344763-DDD47D86-FB83-48BB-AA8D-D02C198FC279

wdtn:P698

n9:14746858

wdt:P698

14746858

p:P1433

wds:Q75344763-C6C97606-FF95-4C32-AD73-6FB6997786E5

wdt:P1433

wd:Q332260

p:P433

wds:Q75344763-CDF60EC6-A54D-4AD5-8136-DC62E1AA6B83

p:P478

wds:Q75344763-B519D4F0-6D1F-46BE-90EA-83FCF3DCC862

wdt:P433

3

wdt:P478

40

p:P356

wds:Q75344763-38D53A0A-947F-4148-9C12-A0A1769BCFB7

wdtn:P356

n11:J.EJCA.2003.07.004

wdt:P356

10.1016/J.EJCA.2003.07.004